Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater overall survival (OS) benefit when treated with nivolumab plus chemotherapy vs chemotherapy alone, whereas high regulatory T-cell signatures were associated with greater OS benefit when treated with nivolumab plus ipilimumab.
- Kohei Shitara
- Yelena Y. Janjigian
- Ming Lei
